Remedy H2: Estimate-miss but strong 2020 expected

Research Note

2020-02-14

12:35

Revenue and EBIT were well below our estimates for the second half of 2019. We make comments on expected future royalty-payments for Control, the outlook for 2020 and the revealed price-tag on the peer-company Insomniac.

Tomas Otterbeck

Kristoffer Lindström

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.